key: cord-0713732-4ro7x2ce
authors: Morin, Nathaniel
title: Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? – GLP-1 Might Play One Too
date: 2020-04-22
journal: Diabetes Res Clin Pract
DOI: 10.1016/j.diabres.2020.108160
sha: e3746c8f9752226fe5ee84829058c36f97ef9ed6
doc_id: 713732
cord_uid: 4ro7x2ce

nan

Hello, I recently came across your commentary on the function of dipeptidyl peptidase 4 (DPP-4), its possible role in coronavirus infection, and your hypothesis that DPP-4 inhibition may play a role in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) treatment 1 . As my role is in surgery, acute systemic inflammation in people with type two diabetes is always on my mind to improve perioperative glycaemia and outcomes. I wanted to add to your discussion based on my experience in this field.

Endogenous cortisol, catecholamines and Interleukin-6 (IL-6) are main drivers in the post-operative stress response, causing insulin resistance and resulting in hyperglycemia in people with diabetes 2 . This effect is so dramatic after cardiac surgery that up to 80% of people develop hyperglycemia regardless of diabetes status 3 . Post-operative IL-6 increase has shown to cause glucacon like peptide 1 (GLP-1) release 4 , and GLP-1 analogue administration has shown efficacy in reducing post-operative hyperglycemia brought on by cardiac surgery 5 . Pre-operative administration of GLP-1 analogues have also shown efficacy in reducing post-operative hyperglycemia 6 , including superiority compared to preoperative long acting insulin 7 . Unfortunately, DPP-4 inhibitors have yet to show the same degree of efficacy in this regard 8,9 . As many people are likely taking GLP-1 analogues while mildly ill with SARS-COV-2, it may also be worthwhile studying the effects of GLP-1 analogues in preventing or reducing the sustained hyperglycemia resulting from systemic inflammation related to SARS-COV-2 infection. Based on their efficacy in preventing and treating hyperglycemia related to systemic inflammation after cardiac and non-cardiac surgery, GLP-1 analogues may play an important future role as well.

Thank you for your time, and stay well soon.

COVID-19 and diabetes: Can DPP4 inhibition play a role?

Postoperative inflammation and insulin resistance in relation to body composition, adiposity and carbohydrate treatment: a randomized controlled study

Perioperative Hyperglycemia Management an update

Interleukin-6 predicts inflammation induced increase of Glucagon like peptide 1 in humans in response to cardiac surgery with association to parameters of glucose metabolism

LIraglutide for perioperative management of hyperglycemia in cardiac surgery patients: a multicenter randomized superiority trial. Diabetes, Obesity and Metabolism

GLP1 Receptor agonist liraglutide is an effective therapeutic option for perioperative glycemic control in type two diabetes within enhanced recovery after surgery (ERAS) protocols

Liraglutide is a perioperative therapeutic option for patients with type two diabetes that undergo elective surgery

Glycaemic efficacy and safety of linagliptin compared to a basal bolus insulin regimen in patients with type two diabetes undergoing non-cardiac surgery: A multicenter randomized clinical trial

Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: A pilot randomized study